Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$48.68 USD
+1.20 (2.53%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $48.68 0.00 (0.00%) 6:44 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Legend Biotech Corporation Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,309 | 1,027 | 884 | 506 | 159 |
Receivables | 100 | 0 | 50 | 75 | 30 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 19 | 10 | 2 | 2 | 1 |
Other Current Assets | 69 | 62 | 13 | 10 | 17 |
Total Current Assets | 1,498 | 1,099 | 949 | 593 | 207 |
Net Property & Equipment | 109 | 105 | 146 | 113 | 70 |
Investments & Advances | 0 | 1 | 2 | 0 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 4 | 3 | 5 | 3 | 1 |
Deposits & Other Assets | 157 | 67 | 10 | 4 | 0 |
Total Assets | 1,849 | 1,331 | 1,118 | 721 | 288 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 20 | 33 | 7 | 5 | 10 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 7 | 10 | 0 | 0 | 0 |
Other Current Liabilities | 186 | 252 | 272 | 154 | 117 |
Total Current Liabilities | 216 | 298 | 280 | 161 | 128 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 281 | 261 | 120 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 55 | 8 | 245 | 278 | 278 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 597 | 587 | 647 | 441 | 411 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 1,251 | 744 | 471 | 280 | -123 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,251 | 744 | 471 | 280 | -123 |
Total Liabilities & Shareholder's Equity | 1,849 | 1,331 | 1,118 | 721 | 288 |
Total Common Equity | 1,251 | 744 | 471 | 280 | -123 |
Shares Outstanding | 181.70 | 164.00 | 153.90 | 129.20 | NA |
Book Value Per Share | 6.89 | 4.54 | 3.06 | 2.17 | 0.00 |
Fiscal Year End for Legend Biotech Corporation Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,292 | 1,303 | 1,309 | 1,424 | 1,516 |
Receivables | 13 | 3 | 100 | 0 | 15 |
Notes Receivable | NA | 0 | 0 | 0 | NA |
Inventories | 19 | 22 | 19 | 18 | 15 |
Other Current Assets | 101 | 86 | 69 | 67 | 67 |
Total Current Assets | 1,425 | 1,414 | 1,498 | 1,509 | 1,613 |
Net Property & Equipment | 105 | 105 | 109 | 110 | 111 |
Investments & Advances | 0 | 1 | 0 | 0 | 1 |
Other Non-Current Assets | NA | 0 | 0 | 0 | NA |
Deferred Charges | NA | 0 | 0 | 0 | NA |
Intangibles | 3 | 3 | 4 | 4 | 2 |
Deposits & Other Assets | 151 | 172 | 157 | 142 | 125 |
Total Assets | 1,798 | 1,775 | 1,849 | 1,839 | 1,931 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 39 | 39 | 20 | 17 | 22 |
Accounts Payable | NA | 0 | 0 | 0 | NA |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | NA |
Current Portion Capital Leases | NA | 0 | 0 | 0 | NA |
Accrued Expenses | NA | 0 | 0 | 0 | NA |
Income Taxes Payable | 7 | 7 | 7 | 10 | 10 |
Other Current Liabilities | 245 | 200 | 186 | 145 | 166 |
Total Current Liabilities | 294 | 250 | 216 | 175 | 201 |
Mortgages | NA | 0 | 0 | 0 | NA |
Deferred Taxes/Income | NA | 0 | 0 | 0 | NA |
Convertible Debt | NA | 0 | 0 | 0 | NA |
Long-Term Debt | 292 | 286 | 281 | 276 | 271 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 9 | 55 | 7 | 7 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | NA |
Total Liabilities | 639 | 611 | 597 | 500 | 524 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 0 | 0 | 0 | NA |
Retained Earnings | 1,159 | 1,164 | 1,251 | 1,340 | 1,407 |
Other Equity | NA | 0 | 0 | 0 | NA |
Treasury Stock | NA | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 1,159 | 1,164 | 1,251 | 1,340 | 1,407 |
Total Liabilities & Shareholder's Equity | 1,798 | 1,775 | 1,849 | 1,839 | 1,931 |
Total Common Equity | 101,158 | 1,164 | 1,251 | 1,340 | 101,406 |
Shares Outstanding | 182.20 | 181.90 | 181.70 | 165.00 | 165.20 |
Book Value Per Share | 555.20 | 6.40 | 6.89 | 8.12 | 613.84 |